BCL-2
Assets acting on this target.
- Class
- Small molecule BCL-2 inhibitor
- Pathway
- Intrinsic (mitochondrial) apoptosis pathway
BCL-2 is a protein that helps cells survive by blocking apoptosis, the programmed cell death process that normally eliminates damaged or unneeded cells. It works within the intrinsic, or mitochondrial, apoptosis pathway, where a family of related proteins constantly balance pro-survival and pro-death signals at the mitochondrial membrane. Many cancer cells, particularly certain blood cancers, produce excess BCL-2, allowing malignant cells that should die to persist and accumulate. Small molecule BCL-2 inhibitors are designed to occupy the groove on BCL-2 that normally sequesters pro-apoptotic partner proteins, releasing them so they can trigger mitochondrial outer membrane permeabilization and commit the cell to death. Because this approach exploits a survival dependency that many tumor cells have come to rely on, it can selectively induce apoptosis in malignant populations while sparing normal cells that are less reliant on BCL-2 for survival. This mechanism is broadly relevant across hematologic malignancies such as leukemias and lymphomas, where BCL-2 overexpression is common, and is being explored in various combination strategies. The approach represents a rational, structure-based way of directly re-enabling a cell's own death machinery rather than relying on external immune or genotoxic mechanisms.
By indication
Related mechanisms
BCL-2 drugs compared
10 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| SonrotoclaxBeqalzi | BeOne Medicines | small molecule | Approved | Approved in Mantle Cell Lymphoma; Phase 3 in Chronic Lymphocytic Leukemia; Phase 2 in Acute Myeloid Leukemia |
| Venetoclax | AbbVie, Roche | small molecule | Approved | Approved in Acute Myeloid Leukemia; Approved in Chronic Lymphocytic Leukemia; Phase 3 in Multiple Myeloma |
| Lisaftoclax | Ascentage Pharma Group Inc. | small molecule | Phase 3 | Phase 3 in Acute Myeloid Leukemia; Phase 3 in Relapsed/Refractory Chronic Lymphocytic Leukemia; Phase 1/2 in Multiple Myeloma; Phase 1/2 in Systemic Lupus Erythematosus |
| Mesutoclax | Beijing InnoCare Pharma Tech Co. | small molecule | Phase 3 | Phase 3 in Acute Myeloid Leukemia; Phase 3 in Mantle Cell Lymphoma; Phase 2/3 in Chronic Lymphocytic Leukemia |
| FCN-338 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | small molecule | Phase 2 | Not recorded |
| Surzetoclax | AbbVie | small molecule | Phase 1/2 | Phase 1/2 in Multiple Myeloma |
| TGRX-814 | Shenzhen TargetRx | small molecule | Phase 1/2 | Phase 1/2 in Acute Myeloid Leukemia |
| BGB-21447 | BeOne Medicines | small molecule | Phase 1 | Phase 1 in HR+/HER2- Metastatic Breast Cancer |
| FXS0683 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | small molecule | Phase 1 | Phase 1 in Acute Myeloid Leukemia |
| Lonitoclax | Lomond Therapeutics Holdings, Inc. | small molecule | Phase 1 | Phase 1 in Acute Myeloid Leukemia |